PIK3CA Mutation clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
Sorry, in progress, not accepting new patients
Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatments
San Francisco, California and other locations
Our lead scientists for PIK3CA Mutation research studies include Hope Rugo.